With the business potentially at an important milestone, we thought we'd take a closer look at Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) future prospects. Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company’s loss has recently broadened since it announced a US$62m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$63m, moving it further away from breakeven. As path to profitability is the topic on Xeris Biopharma Holdings' investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

View our latest analysis for Xeris Biopharma Holdings

Consensus from 6 of the American Pharmaceuticals analysts is that Xeris Biopharma Holdings is on the verge of breakeven. They expect the company to post a final loss in 2025, before turning a profit of US$6.9m in 2026. The company is therefore projected to breakeven around 2 years from today. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 70% is expected, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Underlying developments driving Xeris Biopharma Holdings' growth isn’t the focus of this broad overview, but, take into account that typically pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

Before we wrap up, there’s one issue worth mentioning. Xeris Biopharma Holdings currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. Oftentimes, losses exist only on paper but other times, it can be a red flag.

Next Steps:

There are too many aspects of Xeris Biopharma Holdings to cover in one brief article, but the key fundamentals for the company can all be found in one place – Xeris Biopharma Holdings' company page on Simply Wall St. We've also put together a list of relevant factors you should further research:

1. Historical Track Record: What has Xeris Biopharma Holdings' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Xeris Biopharma Holdings' board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.